Anticholinergic Drugs Not Harmful to Parkinson’s Patients
There was no difference in cognition between Parkinson’s patients taking a high and lower level of anticholinergic medications.
All articles by Jonathan Block
Brain Network Connectivity May Be Behind ADHD
Children with ADHD had weaker connections between three brain networks than children without the condition.
DSM Pioneer, Psychiatrist Robert Spitzer Dies
Dr. Robert L. Spitzer contributed immensely to various editions of the DSM and helped get homosexuality removed as a mental disorder.
Abandoned Antidepressant May Have New Life As Alzheimer’s Drug
In a neurocognitive mouse model, rolipram was able to restore a process in the brain that helps to lower toxic protein levels.
Novel Antidepressant Shows Promise in Phase 1
NSI-189 has demonstrated the ability to produce new brain cells and has been effective in early stage trials.
PTSD Resources For Non-Vets Need Improvement
Research and resources geared toward non-veterans is not sufficient enough to help them.
Drug That Protects Dopamine Cells Eyed as Parkinson’s Treatment
In a mouse model of Parkinson’s, LBT-3727 was able to protect dopamine-producing cells.
Proteins Could be Potential Bipolar Disorder Biomarkers
There was a significant difference in six proteins in those with bipolar I depression compared to the control group.
FDA Committee Looks Unfavorably on Antidepressant Gepirone
The FDA’s Psychopharmacologic Drugs Advisory Committee voted 9-4 that gepirone did not demonstrate substantial effectiveness.
Market for Antidepressants, Anti-Anxiolytics to Decline
The global market for anxiety treatments and antidepressants will decline at a compound annual growth rate of 1.25% between 2014 and 2020.
